Sinaptica Therapeutics

Sinaptica Therapeutics has developed SinaptiStim™, a personalized rTMS (repetitive Transcranial Magnetic Stimulation)  neuromodulation system delivering non-invasive, ML-driven neurostimulation to enhance neuroplasticity in key brain networks to slow the progression of Alzheimer's. Current treatments for Alzheimer’s are minimally effective in delaying cognitive decline, are burdened by IV infusions, brain bleeding/swelling, and require costly MRI monitoring. Sinaptica addresses this by targeting the Default Mode Network (DMN), an area of the brain related to episodic memory,  using a novel approach that enhances neuroplasticity via neurostimulation, offering a safer and more cost-effective alternative for treating Alzheimer’s than invasive anti-amyloid drugs and other non-invasive brain stimulation methods. Sinaptica has been granted FDA Breakthrough Designation for their SinaptiStimTM system.